Mirati Therapeutics to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib

/PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced the presentation of new clinical research...

Related Keywords

United States ,Chicago ,Illinois ,American ,Charles Baum ,Joshuak Sabari ,Alexanderi Spira ,Linkedin ,American Society Of Clinical Oncology ,Twitter ,Prnewswire Mirati Therapeutics Inc ,Drug Administration ,Nasdaq ,Mirati Therapeutics Inc ,Exchange Commission ,Facebook ,Access Program ,Virtual Investor Event ,Clinical Oncology ,Annual Meeting ,Mirati Therapeutics ,New Drug Application ,Accelerated Approval ,Time Oncology Review ,Breakthrough Therapy Designation ,Metastatic Non Small Cell Lung Cancer ,Lung Cancer ,Non Small Cell ,Clinical Science ,Advancing Care ,All Patients With Lung ,Investor Event ,Expanded Access Program ,